vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and LandBridge Co LLC (LB). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $51.0M, roughly 1.5× LandBridge Co LLC). LandBridge Co LLC runs the higher net margin — 35.0% vs -9.6%, a 44.6% gap on every dollar of revenue. On growth, LandBridge Co LLC posted the faster year-over-year revenue change (16.0% vs -16.8%). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (40.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

BIOX vs LB — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$51.0M
LB
Growing faster (revenue YoY)
LB
LB
+32.9% gap
LB
16.0%
-16.8%
BIOX
Higher net margin
LB
LB
44.6% more per $
LB
35.0%
-9.6%
BIOX
Faster 2-yr revenue CAGR
LB
LB
Annualised
LB
40.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
LB
LB
Revenue
$77.6M
$51.0M
Net Profit
$-7.4M
$17.9M
Gross Margin
46.8%
Operating Margin
9.3%
57.2%
Net Margin
-9.6%
35.0%
Revenue YoY
-16.8%
16.0%
Net Profit YoY
-20.2%
15.6%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
LB
LB
Q1 26
$51.0M
Q4 25
$56.8M
Q3 25
$77.6M
$50.8M
Q2 25
$47.5M
Q1 25
$60.6M
$44.0M
Q4 24
$98.8M
$36.5M
Q3 24
$93.3M
$28.5M
Q2 24
$26.0M
Net Profit
BIOX
BIOX
LB
LB
Q1 26
$17.9M
Q4 25
$8.1M
Q3 25
$-7.4M
$8.1M
Q2 25
$7.5M
Q1 25
$-1.6M
$6.5M
Q4 24
$605.2K
$49.3M
Q3 24
$-6.2M
$2.7M
Q2 24
$-57.7M
Gross Margin
BIOX
BIOX
LB
LB
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
LB
LB
Q1 26
57.2%
Q4 25
60.0%
Q3 25
9.3%
60.8%
Q2 25
60.0%
Q1 25
1.5%
57.0%
Q4 24
14.5%
49.4%
Q3 24
2.5%
11.2%
Q2 24
-197.4%
Net Margin
BIOX
BIOX
LB
LB
Q1 26
35.0%
Q4 25
14.2%
Q3 25
-9.6%
15.9%
Q2 25
15.8%
Q1 25
-2.6%
14.7%
Q4 24
0.6%
135.2%
Q3 24
-6.6%
9.3%
Q2 24
-222.1%
EPS (diluted)
BIOX
BIOX
LB
LB
Q1 26
Q4 25
$0.24
Q3 25
$-0.12
$0.26
Q2 25
$0.24
Q1 25
$-0.02
$0.20
Q4 24
$0.00
Q3 24
$-0.10
$-0.04
Q2 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
LB
LB
Cash + ST InvestmentsLiquidity on hand
$15.5M
$29.7M
Total DebtLower is stronger
$433.0K
Stockholders' EquityBook value
$288.3M
Total Assets
$734.9M
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
LB
LB
Q1 26
$29.7M
Q4 25
$30.7M
Q3 25
$15.5M
$28.3M
Q2 25
$20.3M
Q1 25
$38.5M
$14.9M
Q4 24
$29.2M
$37.0M
Q3 24
$32.3M
$14.4M
Q2 24
$24.6M
Total Debt
BIOX
BIOX
LB
LB
Q1 26
$433.0K
Q4 25
$570.7M
Q3 25
$366.1M
Q2 25
$370.9M
Q1 25
$375.5M
Q4 24
$385.5M
Q3 24
$242.4M
Q2 24
$360.8M
Stockholders' Equity
BIOX
BIOX
LB
LB
Q1 26
Q4 25
$340.3M
Q3 25
$288.3M
$272.0M
Q2 25
$266.4M
Q1 25
$345.0M
$217.0M
Q4 24
$346.3M
$211.8M
Q3 24
$346.0M
$97.2M
Q2 24
$296.4M
Total Assets
BIOX
BIOX
LB
LB
Q1 26
$1.4B
Q4 25
$1.4B
Q3 25
$734.9M
$1.1B
Q2 25
$1.1B
Q1 25
$798.2M
$1.0B
Q4 24
$835.2M
$1.0B
Q3 24
$827.3M
$689.9M
Q2 24
$710.5M
Debt / Equity
BIOX
BIOX
LB
LB
Q1 26
Q4 25
1.68×
Q3 25
1.35×
Q2 25
1.39×
Q1 25
1.73×
Q4 24
1.82×
Q3 24
2.49×
Q2 24
1.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
LB
LB
Operating Cash FlowLast quarter
$14.4M
$41.1M
Free Cash FlowOCF − Capex
$40.9M
FCF MarginFCF / Revenue
80.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.30×
TTM Free Cash FlowTrailing 4 quarters
$232.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
LB
LB
Q1 26
$41.1M
Q4 25
$126.3M
Q3 25
$14.4M
$34.9M
Q2 25
$37.3M
Q1 25
$23.3M
$15.9M
Q4 24
$-5.4M
$67.6M
Q3 24
$5.2M
$7.5M
Q2 24
$16.0M
Free Cash Flow
BIOX
BIOX
LB
LB
Q1 26
$40.9M
Q4 25
$122.0M
Q3 25
$33.7M
Q2 25
$36.1M
Q1 25
$15.8M
Q4 24
$66.7M
Q3 24
$7.1M
Q2 24
$15.7M
FCF Margin
BIOX
BIOX
LB
LB
Q1 26
80.3%
Q4 25
214.9%
Q3 25
66.3%
Q2 25
75.9%
Q1 25
36.0%
Q4 24
182.6%
Q3 24
25.1%
Q2 24
60.4%
Capex Intensity
BIOX
BIOX
LB
LB
Q1 26
Q4 25
7.5%
Q3 25
2.3%
Q2 25
2.6%
Q1 25
0.2%
Q4 24
2.7%
Q3 24
1.1%
Q2 24
1.4%
Cash Conversion
BIOX
BIOX
LB
LB
Q1 26
2.30×
Q4 25
15.68×
Q3 25
4.31×
Q2 25
4.98×
Q1 25
2.46×
Q4 24
-8.85×
1.37×
Q3 24
2.80×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

LB
LB

Other$14.2M28%
Easements and other surface-related revenues$11.6M23%
Surface use royalties - related party$11.0M22%
Resource sales$5.2M10%
Resource royalties$4.3M8%
Easements and other surface-related revenues - related party$3.2M6%
Resource royalties - related party$1.3M2%
Resource sales - related party$205.0K0%

Related Comparisons